Valuation: Novavax, Inc.

Market Cap 1.73B 1.55B 1.42B 1.29B 2.41B 164B 2.45B 16.97B 6.81B 86.26B 6.48B 6.34B 272B P/E 2026 *
-20.3x
P/E 2027 * -82.8x
Enterprise Value 1.95B 1.74B 1.6B 1.45B 2.72B 185B 2.77B 19.12B 7.67B 97.2B 7.3B 7.15B 307B EV / Sales 2026 *
5.07x
EV / Sales 2027 * 7.21x
Free-Float
93.06%
Yield 2026 *
-
Yield 2027 * -
1 day-3.72%
1 week+0.90%
Current month-6.75%
1 month-6.84%
3 months+37.33%
6 months+26.47%
Current year+50.00%
1 week 8.95
Extreme 8.9502
10.65
1 month 8.95
Extreme 8.9502
13.38
Current year 6.76
Extreme 6.76
13.38
1 year 6.2
Extreme 6.2
13.38
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
236.5
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/6/26 Exercice

Director

37,760 0.0230%
18/6/26 Free

Director

35,450 0.0216%
25/4/26 Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
-3.72%+0.90%+20.29%+58.74% 1.73B
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.30%+4.73%+49.62%+153.60% 39.44B
Weighted average by Cap. -0.01%+3.65%+49.45%+162.02%

Financials

2026 *2027 *
Net sales 384M 344M 316M 287M 536M 36.45B 546M 3.77B 1.51B 19.17B 1.44B 1.41B 60.47B 282M 252M 232M 210M 393M 26.73B 400M 2.77B 1.11B 14.06B 1.06B 1.03B 44.34B
Net income -91.55M -81.99M -75.42M -68.34M -128M -8.69B -130M -899M -361M -4.57B -344M -336M -14.42B -23.29M -20.86M -19.18M -17.38M -32.49M -2.21B -33.1M -229M -91.83M -1.16B -87.39M -85.53M -3.67B
Net Debt 219M 196M 180M 163M 306M 20.79B 311M 2.15B 864M 10.94B 822M 804M 34.5B 303M 272M 250M 226M 423M 28.79B 431M 2.98B 1.2B 15.14B 1.14B 1.11B 47.76B
Projected Income Statement - Annual - Novavax, Inc.
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
31/10/26 US$10.08 -3.72% 4,060,773
29/10/26 US$10.47 +1.45% 2,800,166
28/10/26 US$10.32 +2.99% 4,748,249
27/10/26 US$10.02 +6.60% 6,774,688
26/10/26 US$9.400 -3.09% 4,941,085
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Novavax, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.47USD
Average target price
14.44USD
Spread / Average Target
+37.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Novavax, Inc.
  1. Stock Market
  2. Stocks
  3. NVAX Stock